VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.89
+2.57%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
Market Cap
$2.59B
MomentumView details →
1D Return
+2.57%
YTD Return
−29.60%
RSI (14)
56.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
Market Cap
$2.59B
RSI (14)
56.2
MomentumView details →
1D Return
+2.57%
YTD Return
−29.60%
SummaryUpdated Jun 1, 2026
Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company founded in 2016 and headquartered in Brisbane, California. Originally incorporated as Trucode Gene Repair, Inc., the company changed its name to Vera Therapeutics in April 2020 and went public in May 2021. The company focuses on developing and commercializing treatments for patients with serious immunological diseases, with its primary emphasis on rare kidney diseases and viral infections that affect immunocompromised patients.
Similar companies
Latest newsMore news →
Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk for disease progression.55d agoVera Therapeutics announced the appointment of Nancy Boman as Chief Regulatory Officer and the planned retirement of William Turner.58d agoVera Therapeutics received FDA accelerated approval for TRUTAKNA for adult patients with primary IgA nephropathy.59d ago